Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function by Martine R. van Schouwenburg et al.
ORIGINAL INVESTIGATION
Anatomical connection strength predicts dopaminergic
drug effects on fronto-striatal function
Martine R. van Schouwenburg & Marcel P. Zwiers &
Marieke E. van der Schaaf & Dirk E. M. Geurts &
Arnt F. A. Schellekens & Jan K. Buitelaar &
Robbert J. Verkes & Roshan Cools
Received: 16 October 2012 /Accepted: 9 January 2013 /Published online: 13 February 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Rationale The neurotransmitter dopamine plays a key role
in cognitive functions that are associated with fronto-striatal
circuitry and has been implicated in many neuropsychiatric
disorders. However, there is a large variability in the direc-
tion and extent of dopaminergic drug effects across
individuals.
Objectives We investigated whether individual differences
in dopaminergic drug effects on human fronto-striatal func-
tioning are associated with individual differences in white
matter tracts.
Methods The effects of the dopamine receptor agonist bro-
mocriptine were assessed using functional magnetic reso-
nance imaging in 22 healthy volunteers in a placebo-
controlled, double-blind, within-subject design. Human psy-
chopharmacology and functional neuroimaging were com-
bined with functional connectivity analyses and structural
connectivity analyses to establish a link between dopami-
nergic drug effects on fronto-striatal function and fronto-
striatal anatomy.
Results We demonstrate that bromocriptine alters functional
signals associated with attention switching in the basal
ganglia. Crucially, individual differences in the drug’s effect
on these signals could be predicted from individual differ-
ences in fronto-striato-thalamic white matter tracts, as
indexed by diffusion tensor imaging. Anatomical fronto-
striatal connectivity also predicted drug effects on switch-
related functional connectivity between the basal ganglia
and the prefrontal cortex.
Conclusions These data reinforce the link between dopa-
mine, cognition and the basal ganglia and have implications
for the individual tailoring of dopaminergic drug therapy
based on anatomical fronto-striatal connection strength.
Keywords Prefrontal cortex . Attention . Basal ganglia .
Connectivity . Dopamine . fMRI
Introduction
Dopamine is implicated in many neuropsychiatric disorders,
such as schizophrenia, attention deficit hyperactivity disor-
der and addiction. These disorders are invariably accompa-
nied by cognitive and attention deficits. Therefore, a better
understanding of the mechanisms by which dopamine
affects cognition and attention is crucial. However, individ-
ual variability poses a major challenge for dopaminergic
drug research. While dopaminergic drugs improve cognitive
function in some individuals, these drugs can impair cogni-
tive function in others. Hence, the isolation of dopaminergic
drug effects requires us to take into account such individual
variability (Cools et al. 2007, 2009; Kimberg et al. 1997;
Mehta and Riedel 2006; Wallace et al. 2011). Here, we
investigated whether individual differences in dopaminergic
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drug effects on human cognitive processing could be pre-
dicted based on individual differences in white matter tracts.
Dopamine acts primarily as a neuromodulator, poten-
tiating or attenuating synaptic transmission of classical
neurotransmitters (Seamans and Yang 2004). At the
level of the striatum, it stimulates dopaminergic recep-
tors that are located near glutamatergic fronto-striatal
and thalamo-striatal synapses, thus modulating informa-
tion flow through fronto-striato-thalamo-frontal loops
(Moss and Bolam 2010). One corollary of this observa-
tion is that dopamine’s functional effects might vary as
a function of fronto-striato-thalamo-frontal anatomical
infrastructure. Specifically, dopaminergic drug effects
might depend on individual differences in fronto-
striatal and/or thalamo-striatal connections. We used
pharmacological functional magnetic resonance imaging
(fMRI) to assess the effects of the dopamine receptor
agonist bromocriptine on fronto-striatal activity during
attention switching, as a function of anatomical connec-
tivity as measured with diffusion tensor imaging. We
anticipated that individual differences in dopaminergic
drug effects on fronto-striatal function would depend on
fronto-striato-thalamic anatomical connectivity.
This approach also enabled us to assess the pervasive but
untested hypothesis that dopamine can alter prefrontal func-
tion indirectly by acting on the basal ganglia and by mod-
ulating information flow through fronto-striato-thalamo-
frontal circuitry (Hazy et al. 2007). So far, most studies have
emphasized the role of the prefrontal cortex in dopamine’s
effects on cognition and attention. They demonstrate that
dopamine can act on the prefrontal cortex to regulate atten-
tional control (Noudoost and Moore 2011). However, dopa-
mine receptors are particularly abundant in the basal
ganglia; accordingly, dopamine might also act on the basal
ganglia to modulate attentional control. This hypothesis is
supported by a number of observations. First, pharmacolog-
ical fMRI studies in humans have shown that dopamine
modulates functional signals in the basal ganglia during a
range of paradigms that require attention switching, such as
task switching (Aarts et al. 2010), updating of working
memory (Cools et al. 2007) and reversal learning (e.g.
Dodds et al. 2008). Second, attentional control is disturbed
in Parkinson’s disease, a disorder that is characterized by
relatively selective dopamine depletion in the basal ganglia.
Third, dopamine has been shown to modulate fronto-
striatal functional connectivity in humans as well as in
animals (Goto and Grace 2005; Honey et al. 2003;
Nagano-Saito et al. 2008; Stelzel et al. 2010), in line
with the hypothesis that dopamine might modulate the
information flow through fronto-striato-thalamo-frontal
circuits (Alexander et al. 1986).
The present study contributes to existing literature by
investigating directly the link between dopaminergic drug
effects on the basal ganglia, anatomical fronto-striatal con-
nectivity and functional fronto-striatal connectivity.
Methods and materials
Subjects
Twenty-eight healthy volunteers participated in this study.
Five subjects were excluded due to excessive movement in
the scanner (more than two times the voxel size, e.g. trans-
lation >6 mm), data acquisition problems or image prepro-
cessing problems. One subject had less than 10 switch trials
and therefore was excluded. Accordingly, data are reported
from 22 subjects (11 males, age [mean ± SEM] 21.3 ± 0.4).
During an initial intake session, participants were
screened by a medical doctor and a research nurse to ex-
clude (a history of) psychiatric diseases, medical illness,
substance abuse or a family history of psychiatric diseases
(Supplementary Materials). In addition, the attention switch-
ing paradigm was practised in the MR scanner, while we
obtained a structural scan and a diffusion-weighted scan.
All subjects gave written informed consent and were
compensated for participation. The study was approved by
the local ethics committee (CMO region Arnhem/Nijmegen,
The Netherlands).
Pharmacological design and procedures
Subjects were tested on two occasions, once on placebo and
once after intake of a single oral dose of the dopamine receptor
agonist bromocriptine (1.25 mg). The order of administration
was randomized according to a counterbalanced, placebo-
controlled and double-blind design (11 subjects received bro-
mocriptine first, 11 subjects received placebo first). Timing of
dosing was optimized for detecting drug effects during the
fMRI scan which started 110 min after drug intake. Subjects
were instructed to abstain from alcohol 24 h before drug intake
and were not allowed to smoke or drink any caffeinated drinks
on the day of testing. Blood samples, Bond and Lader
visual analogue mood scales (Bond and Lader 1974)
and measures of heart rate and blood pressure were
obtained throughout the day. In addition, background
neuropsychological tests (block completion, number can-
cellation, verbal fluency and digit span) were assessed
at the end of the day (Supplementary Materials).
Paradigm
An attention switching paradigm was employed in which
subjects switched attention when they detected a change in
the stimulus exemplars of a non-selected category of face/-
scene stimuli. It was developed as an ecologically valid
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model of attention switching, because attention switches in
real are often triggered by stimuli in a currently unattended
stream of information. We have shown previously that this
paradigm reliably recruits a fronto-striatal network, and it is
therefore well suited to assess the effects of dopaminergic
drugs on fronto-striatal functioning (van Schouwenburg et
al. 2010). Subjects were presented with a series of stimulus
pairs, each consisting of a superimposed face exemplar and
scene exemplar (Fig. 1a). Subjects were instructed to select
one of four exemplars by making a left or right response,
depending on the location of the exemplar of their choice.
This exemplar was then set as the correct stimulus, and
subjects were instructed to continue selecting that stimulus
on subsequent trials. After a variable number of correct
trials, exemplars of the ignored category were replaced with
novel exemplars. Subjects were instructed to switch atten-
tion to this other category and to choose one of the two
novel exemplars, as soon as they detected a change. Trials
on which novel exemplars were introduced and on which
subjects detected the change and switched to one of the
novel exemplars where classified as switch trials (Fig. 1c).
On some trials, subjects failed to detect the novel exemplars
and kept responding to the previously correct exemplar
(non-switch trials). In this case, negative feedback was
presented, usually leading subjects to switch on the subse-
quent trial. Trials on which no novel stimuli were introduced
were defined as repeat trials (Fig. 1b). Four subjects had less
that 10 non-switch trials on one of two sessions. Therefore,
we focused all analyses on switch and repeat trials.
Subjects were presented with an average of 349 trials
(SEM 5), on which novel exemplars were introduced on
82 trials. The sequence of the faces and scenes presented
was randomized across subjects but was constant within
subjects across the two sessions. For more details on the
paradigm, see van Schouwenburg et al. (2010).
Behavioural analysis
Behavioural analysis focused on the switch likelihood,
which was calculated as the percentage of immediate
switches in response to a novel stimulus, and reaction time
analyses. Excluded from reaction time analyses were the
first trial of each block, all trials on which subjects received
negative feedback and trials following negative feedback.
For each subject, we calculated the median reaction time,
rather than mean reaction time, to minimize the influence of
outliers. Next, we calculated the mean reaction times ± SEM
across subjects. Planned contrasts were assessed using
repeated-measures ANOVAs or paired sample t tests. The
statistical threshold was set at p < 0.05 (two-tailed).
fMRI data acquisition and analysis
Whole-brain functional images and a T1-weighted anatom-
ical scan were obtained on a Siemens 3-T MR scanner (for
scanning parameters, see Supplementary Materials). Mass-
univariate data analysis was performed using SPM5 soft-
ware (Wellcome Trust Centre for Neuroimaging, London,
Fig. 1 Subjects were instructed to select one stimulus exemplar (left
versus right) within one category (faces versus scenes) and to keep
selecting that same exemplar for a number of trials, until novel exem-
plars were introduced in the non-selected category, requiring a switch
in attention. a Stimuli consisted of superimposed exemplars of a face
and a scene. Stimulus pairs were presented twice within each trial and
the combination of face and scene was reversed on the second presen-
tation relative to the first, enabling us to identify the attended stimulus.
Feedback was presented after each trial and was positive only if the
subject selected the correct stimulus twice within the trial. Red boxes
indicate a possible response sequence. b, c Two consecutive trials
constituting our two trial types of interest. The stimuli are displayed
schematically for illustrative purposes (F1, face 1; S1, scene 1; F2, face
2; S2, scene 2). Attended stimuli are displayed in italic font. b Repeat
trial: on the first trial, the subject attends to F1. On the next trial, no
novel stimuli are introduced and the subject keeps attending to F1. The
second trial is thus defined as a repeat trial. c Switch trial: The subject
attends to F1 on the first trial. On the second trial, novel stimuli of the
non-selected category, in this case scenes, are introduced (S3 and S4).
The subject detects this change and switches attention to one of two
novel stimuli (here S3)
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UK). Preprocessing procedures of functional images were
performed as described previously (van Schouwenburg et
al. 2010).
In a general linear model (GLM), we included two
regressors of interest: switch and repeat trials. In addi-
tion, we modelled non-switch trials (regressor 3), trials
following non-switch trials (regressor 4), all error trials,
missed trials and trials after an error or after a missed
trial (regressor 5), and the six realignment parameters
(regressors 6–11) as regressors of no interest. All
paradigm-related regressors were modelled as delta
functions at the onset of the first stimulus-pair presen-
tation within a trial and were convolved with a canon-
ical haemodynamic response function (hrf) including
time derivatives. Time series were high-pass filtered
(128 s).
Parameter estimates for the regressors of interest
were estimated at the first level, for each session sep-
arately, and then used in a second level random effects
2 × 2 factorial design with the within-subject factors
trial type (switch and repeat) and drug (placebo and
bromocriptine).
To assess drug effects in the basal ganglia, we de-
fined a volume of interest (VOI) as a sphere with a 6-
mm radius (size of the applied smoothing kernel)
around the peak voxel for the switch versus repeat
contrast averaged across drug conditions within the left
(MNI coordinates, −12 2 0) and right (14 2 0) basal
ganglia [defined as the caudate, putamen and pallidum,
according to the automated anatomical labelling (AAL)
interface (Tzourio-Mazoyer et al. 2002)]. (Similar results
were obtained when definition of the VOI was based on
clusters in the basal ganglia showing an increase for
switch versus repeat, see Supplementary Material). The
left and right VOIs were then combined. Definition of
VOIs and VOI data extraction were done using
MarsBaR (Brett et al. 2002). Note that the numbers of
switch and repeat trials were matched between drug
conditions. This allowed us to define a VOI based on
the switch minus repeat contrast across drug conditions
without introducing a bias towards finding a drug effect
(Kriegeskorte et al. 2010).
The main effects of task (switch versus repeat) were
tested and displayed at a threshold of p < 0.05 family-
wise error (FWE)-corrected for the whole brain (pFWE).
Drug effects were assessed at the voxel level, corrected
for multiple comparisons across our VOI in the basal
ganglia (defined functionally, as described above)
(psvc < 0.05). In addition, exploratory analyses were
performed across the whole brain (pFWE < 0.05).
Figures were displayed using MRIcroN (Rorden et al.
2007). SPMs were superimposed on a skull-stripped
template in MNI space, unless indicated otherwise.
Diffusion tensor imaging analysis
To determine anatomical connectivity, we acquired dif-
fusion tensor images (DTI). Raw DTI data were prepro-
cessed using an in-house software (Zwiers 2010). The
DTI images were realigned and eddy current-corrected
by residual error minimization of the diffusion tensor
model (Andersson and Skare 2002). Susceptibility-
induced echo-planar imaging distortions were corrected
by warping the images to the distortion-free T1 refer-
ence image (Studholme et al. 2000) using an in-house
developed implementation (Visser et al. 2010).
Diffusion tensors were then robustly estimated using
our artefact-insensitive compute algorithm (Zwiers 2010).
Mean diffusivity (MD) and fractional anisotropy (FA)
measures were computed from the diffusion tensor eigen-
values. FA and MD maps were normalized to the T1
ICBM template using the unified segmentation parame-
ters of the structural image and spatially smoothed using
a Gaussian kernel of 8-mm full width at half maximum.
The resulting FA and MD maps were then tested
using a second-level one-sample t test, with the drug
effect on basal ganglia blood oxygenation level-
dependent (BOLD) signal for the switch versus repeat
contrast as a covariate. This drug effect was calculated
for each subject separately by subtracting the average
switch-related BOLD signal across the basal ganglia
VOI on placebo from the average switch-related BOLD
signal across the basal ganglia VOI on bromocriptine. FA
results were masked by a threshold mask of FA > 0.2.
Correlations between FA/MD values and drug effects on
basal ganglia BOLD signal were assessed at the voxel level,
corrected for multiple comparisons across the functionally
defined VOI in the basal ganglia (psvc < 0.05). In addition,
exploratory analyses were performed across the whole brain
(pFWE < 0.05).
Fibre tracking
The FA region showing a significant correlation with the
drug effect on basal ganglia BOLD signal was then used
for probabilistic diffusion tractography to identify white
matter tracts connecting with this location. More specif-
ically, we defined a VOI as a sphere with a radius of
6 mm around the peak voxel of the correlation (MNI
coordinates, 18 6 0). For each subject, this VOI was
brought back into native space, using the inverse of the
computed normalization parameters. FMRIB’s Diffusion
Toolbox (part of FMRIB’s Software Library) was used to
build up distributions on diffusion parameters at each
voxel, allowing for crossing fibres (Behrens et al. 2007)
and subsequent probabilistic tracking from the VOI to all
other voxels in the brain (using standard settings). To
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eliminate spurious connections, tractography in individual
subjects was thresholded to include only voxels through
which at least 50 samples had passed (out of 5,000).
These individual tracts were then binarized and summed
across subjects to produce group probability maps. In
these maps, each voxel value represents the number of
subjects in whom the pathway passes through that voxel.
Results were thresholded to display only those paths that
were present in at least 50 % of the subjects (11 out of
22). A similar approach has been used previously (e.g.
Boorman et al. 2007; Floel et al. 2009).
Psychophysiological interaction analysis
Functional connectivity was assessed using psychophysio-
logical interaction (PPI) analysis (Friston et al. 1997). PPI
works under the assumption that the degree to which the
BOLD signal in one area can be predicted, based on BOLD
signal in another, corresponds to the contribution of the
second region to the first region. The PPI then assesses
whether this contribution changes over experimental condi-
tions. In other words, it assesses whether region A shows
higher or lower connectivity with region B, during condition
C, compared with condition D. Time series were extracted
from a seed voxel in the basal ganglia that showed an
increase in BOLD signal during switching (versus repeat),
for each subject individually. Because the exact locations of
activation maxima varied across subjects, we determined the
individual peak voxels in the basal ganglia, using the con-
straints that it (1) exceeded a threshold of p < 0.05
(uncorrected) in the switch versus repeat contrast and (2)
was within 6 mm of the group maximum (MNI coordinates,
16 0 −2) of the drug effect on the switch versus repeat
contrast. To summarize the regional time series, we com-
puted the first eigenvector across all suprathreshold voxels
(p < 0.05 uncorrected) within 3 mm of this peak voxel. The
time series were then multiplied by a vector coding for the
experimental conditions (switch versus repeat) to obtain the
PPI.
On the subject level, we included the PPI as a regressor
of interest in a GLM. The experimental conditions and the
extracted time series were modelled as additional regressors,
in order to assess the PPI estimates over and above shared
functional activation and task-independent correlations in
BOLD signal between the seed and other regions. This
approach ensures that any obtained PPI results are indepen-
dent of univariate results. These regressors were convolved
with a canonical hrf and high-pass filtered (128 s). In addi-
tion, the six realignment parameters were modelled. The PPI
analysis was performed for each session separately.
The difference between PPI maps on the drug and place-
bo session was calculated for each subject. These difference
maps were then brought to the second random effects level
in a one-sample t test, with FA values as a covariate. These
FA values were extracted from the region showing a signif-
icant correlation with the drug effect on switch-related
BOLD signal in the basal ganglia (as shown in Fig. 4a).
Our functional connectivity analyses aimed to reveal that
drug effects on the switch-related basal ganglia signal were
accompanied by drug effects on functional connectivity
between the basal ganglia and the prefrontal cortex. To this
end, we focused our functional connectivity analyses on a
prefrontal region which we know, based on our previous
study with this task (van Schouwenburg et al. 2010), to be
involved in attention switching: the right inferior frontal
gyrus (IFG). Selection of this region is further justified
based on other studies suggesting that this region plays an
important role in the selective focusing of attention on
currently relevant information (Gazzaley et al. 2004;
Hampshire et al. 2007; Petrides and Pandya 2009). We
combined subregions of the right IFG according to the
AAL interface (Tzourio-Mazoyer et al. 2002) to obtain an
anatomical VOI.
Drug effects were assessed at the voxel level, corrected
for multiple comparisons across the VOI (psvc < 0.05). In
addition, exploratory analyses were performed across the
whole brain (pFWE < 0.05).
Independence of analyses
We would like to emphasize here that we are very well
aware of the danger of double dipping and circular analyses
(Kriegeskorte et al. 2009) and that the effects derived from
the univariate fMRI analyses, the PPI analysis and the
DTI/FA analyses are all independent of each other. In the
following paragraph, we summarize our analysis steps and
reiterate why they are not circular. First, the drug effect on
switch-related BOLD signal was assessed within a basal
ganglia region that responded to the main effect of switch
versus repeat, collapsed across drug sessions. Thus, drug
effects were calculated within a region that was selected
from the same dataset. Nevertheless, this analysis is not
biased because the main task contrast (switch versus repeat)
and the interaction (drug × task) contrast are orthogonal
(Friston et al. 2006). In addition, the actual main and inter-
action effects were also orthogonal, because the numbers of
switch and repeat trials were matched between drug sessions
(Kriegeskorte et al. 2009). In the second step, we calculated
the correlation between FA values and the drug effect on
switch-related BOLD signal. This was done within this
same basal ganglia region of interest. This analysis is not
biased, because the DTI and BOLD datasets are two sepa-
rate, independent datasets. The third step was the PPI anal-
ysis, which was conducted using a seed region in the basal
ganglia that was calculated based on the drug effect on
switch-related BOLD signal. This analysis is also not
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biased, because the inclusion of seed and task-related
regressors in the PPI model ensures that any obtained
PPI results are over and above shared functional activa-
tion and task-independent correlations in BOLD signal
between the seed and other regions. Thus, the PPI
results are independent of the univariate fMRI results.
Our final step was to calculate the correlation between
FA values, extracted from the basal ganglia region that
correlated with the drug effect on BOLD, and the PPI
effects, which were calculated using a seed defined
based on the drug effect on BOLD. Although perhaps
more counterintuitive, it is critical to realize that this
analysis is also not biased, for the same reason as
mentioned above: PPI results are independent of univar-
iate results.
Results
Neural responses during attention switching
Consistent with our previous study (van Schouwenburg et
al. 2010), attention switching increased BOLD signal in a
network of regions. These included the basal ganglia, IFG,
thalamus, insula, hippocampus, anterior cingulate cortex/-
supplementary motor area, inferior and superior parietal
cortex, visual association cortex and midbrain (Fig. 2,
Table 1).
Dopaminergic drug effects during attention switching
To investigate the effects of dopamine on this attention
switching network, we compared BOLD signal after
administration of the dopamine D2 receptor agonist bro-
mocriptine with BOLD signal after placebo. Based on
prior work (Cools et al. 2007, 2009) and the distribution
of D2 receptors in the brain, we expected bromocriptine
to act on the basal ganglia. Consistent with this predic-
tion, bromocriptine increased BOLD signal selectively
in the task-active regions of the basal ganglia during the
switch trials relative to the repeat trials (t = 3.91, psvc =
0.005) (Fig. 3). No other effects were observed at pFWE
< 0.05 across the whole brain, although we report
subthreshold effects (at puncorrected < 0.001) in the
Supplementary Materials for completeness (Table S2).
This result supports previous findings that show the
basal ganglia as the site of action of dopaminergic drug
effects on attention switching (Cools et al. 2007; Dodds
et al. 2008). However, large individual differences were
observed in the degree to which bromocriptine modulat-
ed BOLD signal in this region during switching. While
bromocriptine increased BOLD signal in some subjects,
it decreased BOLD signal in others (Fig. 3b).
Correlations between drug effects and white matter structure
Next, we assessed whether these drug effects in the basal
ganglia were associated with individual differences in the
underlying white matter structure. To this end, we
extracted BOLD signal from our functional basal ganglia
VOI for each subject and calculated the difference be-
tween the bromocriptine session and the placebo session.
These values were entered as a covariate in a second-
level GLM to assess associations with whole-brain FA
values, a measure of white matter integrity. This revealed
a significant association between the drug effect on basal
ganglia BOLD signal and FA values in a region located
in the anterior limb of the capsula interna (t = 4.86,
psvc = 0.003) (Fig. 4a). This region was immediately
adjacent to the region in which bromocriptine exerted
its effect (Fig. 4c). The association was negative, such
that bromocriptine enhanced BOLD signal in the basal
ganglia of subjects with low local white matter integrity
while decreasing BOLD signal in the basal ganglia of
subjects with high local white matter integrity (Fig. 4b).
There were no other effects at pFWE < 0.05 across the
whole brain. We report subthreshold effects at puncorrected
< 0.001 in the Supplementary Materials for completeness
(Table S3).
Probabilistic diffusion tractography
To identify the white matter tracts connecting with the
region in which the drug–FA association was found, we
used the cluster found in the capsula interna as a seed region
for probabilistic diffusion tractography (Behrens et al.
Fig. 2 Statistical parametric
map of the main effect of
attention switching (switch
versus repeat), across drug
sessions (unmasked). The bar
indicates t values, and the
figures are thresholded for a t
value of 5.10, corresponding to
a p value of 0.05 FWE-
corrected for multiple
comparisons
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2007). White matter fibres were revealed in a fronto-striato-
thalamic tract, running from the basal ganglia to the IFG and
from the basal ganglia to the thalamus, extending into the
midbrain (Fig. 5a).
Drug effects on functional connectivity
We predicted that dopamine would also alter functional
connectivity between the prefrontal cortex and basal gan-
glia. Thus, next we investigated whether drug effects on
functional (switch-related) connectivity between the basal
ganglia and right IFG also depended on white matter
integrity.
In line with our predictions, whole-brain analyses
revealed that FA values associated with the drug effect on
the basal ganglia were also associated with the drug effect
on functional connectivity between this region and the right
IFG (MNI coordinates, 48 24 22; t = 6.17; psvc = 0.009). The
cluster was localized close to the endpoint of the anatomical
fronto-striato-thalamic tract revealed by our tractography
analyses (Fig. 5b). Thus, consistent with our prediction,
dopaminergic drug effects on the basal ganglia during at-
tention switching were accompanied by dopaminergic drug
effects on functional fronto-striatal connectivity, in an
anatomy-dependent manner. Note that we did not find a
main effect of drug on functional connectivity, that is, when
white matter integrity was not taken into account.
Table 1 Main effects of task
(switch versus repeat), p < 0.05
FWE-corrected, with a contigu-
ous voxel cluster threshold k > 5.
Peak voxels were localized using
the SPM Anatomy Toolbox
(Eickhoff et al. 2007)
Region Cluster size Local maximum Cluster
statistics
x y z t value
Insula 755 −32 22 0 17.40
Supplementary motor area/anterior cingulate cortex 2,590 −4 18 44 17.13
Inferior frontal gyrus 1,571 −42 6 30 15.49
Insula/inferior frontal gyrus 3,355 32 26 2 14.43
Midbrain/thalamus/basal ganglia 2,425 −6 −28 −6 12.25
Middle/superior frontal gyrus 861 −24 0 54 11.92
Inferior/superior parietal lobule 1,881 34 −46 46 11.73
Inferior/superior parietal lobule 2,497 −46 −40 42 11.35
Inferior temporal gyrus 72 −44 −58 −8 9.30
Inferior temporal gyrus/fusiform gyrus 351 30 −34 −20 7.32
Posterior cingulate cortex 62 −4 −28 28 6.96
Fusiform gyrus 30 −28 −54 −10 6.29
Middle frontal gyrus 6 −32 52 24 5.65
Calcarine gyrus 7 −12 −76 8 5.65
Precuneus 9 22 −56 22 5.41
Fig. 3 a Whole-brain statistical parametric map of drug effects on
switch-related BOLD signal. The statistical parametric map is masked
by the main effect of attention switching (thresholded at p < 0.001
uncorrected). The bar indicates t values of the drug effect (bromocrip-
tine–placebo), and the figure is thresholded for a t value of 3.19,
corresponding to a p value of 0.001 uncorrected for multiple compar-
isons. b Shown are individual differences in drug effects on switch-
related BOLD signal from the basal ganglia, extracted from the cluster
displayed in a
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Additional analyses
A number of additional analyses were performed to exclude
possible confounding factors. Using voxel-based morphom-
etry analyses, we excluded the possibility that our white
matter correlations were in fact driven by differences in grey
matter. Moreover, while we found an association between
the drug effect on switch-related basal ganglia BOLD signal
with FA, no such association was found with MD. This
indicates that our results cannot be explained in terms of
differences in cell density (as measured with MD). Instead,
our results likely reflect directional (axonal) organization (as
measured with FA). For more details on these supplementa-
ry analyses, see Supplementary Materials.
Fig. 4 aWhole-brain statistical
parametric map (unmasked) of
association between fractional
anisotropy and drug effect on
switch-related basal ganglia
(BG) BOLD signal,
superimposed on the mean
fractional anisotropy image
from all participants. The bar
indicates t values, and the figure
is thresholded for a t value of
3.55, corresponding to a p value
of 0.001 uncorrected for
multiple comparisons. b Data
were extracted from the
correlated cluster and plotted
for illustration purposes. c
Overlap between drug effect on
switch-related basal ganglia
BOLD signal (green) and its
association with fractional
anisotropy (red)
Fig. 5 a Group probability map of tracts generated by probabilistic
tractography from FA clusters correlating with drug effect on basal
ganglia BOLD signal. The bar indicates the number of subjects con-
taining the path, and the map is thresholded such that only tracts that
were found in at least 50 % of the subjects (11 out of 22) are included.
bWhole-brain statistical parametric map (unmasked) of the drug effect
on functional connectivity from a basal ganglia seed, as assessed by
PPI (blue/green), as a function of individual differences in FA. The bar
indicates t values, and the figure is thresholded for a t value of 3.55,
corresponding to a p value of 0.001 uncorrected for multiple compar-
isons. White matter tracts derived from probabilistic tractography are
displayed in yellow
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Behavioural analyses
Reaction times were significantly slower on switch trials
compared with repeat trials (F1, 21 = 107.0, p < 0.0001).
There was no main effect of drug (F1, 21 = 1.4, p = 0.2) or an
interaction between drug and trial type (F1, 21 = 1.1, p = 0.3)
(RT placebo: switch, 1,030 ± 53; repeat, 746 ± 36) (RT
bromocriptine: switch, 1,098 ± 73; repeat, 774 ± 44).
Bromocriptine also had no effect on switch likelihood.
Mean switch likelihood was not significantly different be-
tween the placebo session (67.2 ± 4.1 %) and the bromo-
criptine session (64.7 ± 3.9 %) (t1, 21 = 1.2, p = 0.3), also not
when individual differences in FA were taken into account.
There were no brain–behaviour associations.
Drug effects on physiological measurements,
neuropsychological tests and mood ratings
Bromocriptine significantly decreased prolactin levels and
systolic and diastolic blood pressure, indicating that bromo-
criptine reached the systemic circulation. Drug effects were
not attributable to non-specific drug effects on mood and
global cognitive functioning, as bromocriptine did not affect
general cognitive performance or mood, in line with previ-
ous studies (Cools et al. 2007; van der Schaaf et al. 2012)
(see Supplementary Materials).
Discussion
Dopaminergic drug effects vary greatly between individuals
such that the same drug can exert effects in opposite directions.
Our study establishes an important new link between dopami-
nergic drug effects on fronto-striatal function and white matter
integrity of anatomical fronto-striato-thalamic connections.
More specifically, we found that the effect of bromocriptine
on functional signals in the basal ganglia and fronto-striatal
connectivity was significantly associated with anatomical
fronto-striato-thalamic connectivity. Bromocriptine had dia-
metrically opposite effects in subjects with high and low white
matter tract integrity, as indexed by fractional anisotropy val-
ues. Fractional anisotropy relies on several microstructural
properties of white matter tissue, such as the level of axon
myelination, intact axonal membranes, fibre density and fibre
diameter (Beaulieu 2002). This suggests that bromocriptine had
opposite effects as a function of neuronal communication effi-
ciency, in line with the observation that dopamine acts as a
neuromodulator (Moss and Bolam 2010).
Our approach resembles that used previously to link
anatomical connectivity with individual differences in behav-
iour (Forstmann et al. 2008; Tuch et al. 2005) and functional
connectivity (Boorman et al. 2007; Neubert et al. 2010). For
example, it was shown that individual differences in response
inhibition performance depended on fractional anisotropy in
the IFG (Forstmann et al. 2008). However, to our knowledge,
no previous work has revealed associations between neuro-
chemical (drug) effects and anatomical connectivity. This
finding should have important implications for neuropsychi-
atric drug treatment. For example, taking into account white
matter integrity might contribute to individual tailoring and
thus optimization of drug treatment strategies in dopamine-
related neuropsychiatric disorders.
The finding that bromocriptine had diametrically opposite
effects as a function of anatomy is reminiscent of the inverted-
U-shaped relationship between dopamine and cognitive func-
tion (Cools et al. 2007; Kimberg et al. 1997). Dopaminergic
drugs are beneficial for some subjects, while impairing func-
tioning in others. In line with this, we found no main effect of
drug on functional connectivity. However, when taken into
account anatomical connectivity, these individual differences
could be explained. So far, individual differences in dopami-
nergic drug effects have not been linked to brain structure.
Previous studies found individual differences in dopaminergic
drug effects to depend on baseline working memory capacity,
presumably reflecting individual differences in baseline dopa-
mine levels as a consequence of genetic predisposition (Cools
and D’Esposito 2011; Cools et al. 2009). We did not find an
association between drug effects and baseline workingmemory
capacity (as measured with listening span). An important aim
for future work is to assess how baseline neurochemical, ge-
netic and anatomical factors interact to determine drug efficacy.
The drug–FA association, revealed by whole-brain anal-
ysis, was remarkably regionally selective. Indeed, the effect
was restricted to a region in the capsula interna transversing
the basal ganglia, immediately adjacent to the region that
was modulated by the drug. Probabilistic tractography
revealed that this white matter region projected to the IFG,
and the thalamus, extending into the midbrain. Furthermore,
individual differences in white matter integrity predicted
drug effects on functional connectivity between the basal
ganglia and an inferior frontal cluster that was located right
next to the inferior frontal extension of these tracts. These
findings are in line with the suggestions that dopamine acts
on the basal ganglia to alter information flow through ana-
tomical fronto-striatal-thalamic circuits.
We and others have shown previously that dopamine can
modulate cognitive BOLD signal in the basal ganglia, partic-
ularly during tasks that require cognitive flexibility (Cools et
al. 2007; Dodds et al. 2008; Jocham et al. 2009). Following
these observations, we focused our analyses on the basal
ganglia, where we found a main effect of drug in line with
these previous studies. We would like to point out here that
fMRI does not allow us to assess whether the observed drug
effects are a direct effect of drugs acting on the basal ganglia
or secondary from effects elsewhere. For example, previous
studies showed that dopamine modulates cognitive BOLD
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signal in the prefrontal cortex (Gibbs and D’Esposito 2005a,
b) as well as functional connectivity between the basal ganglia
and the prefrontal cortex (Krugel et al. 2009; Nagano-Saito et
al. 2008; Stelzel et al. 2010; Wallace et al. 2011). As a
consequence of the strong anatomical (and functional) con-
nectivity within the fronto-striatal network, dopamine might
modulate this network as a whole, rather than single regions
within this network. The present work substantiates this idea
by showing that the link between drug effects on functional
fronto-striatal connectivity is mediated by anatomical connec-
tivity between the basal ganglia and the prefrontal cortex.
The present study investigated the effect of bromocriptine
on a task that required a switch in attention in response to novel
stimuli. Such switching depends on multiple subcomponent
processes, including novelty detection, inhibition of a previous
stimulus–response association, and selection of a novel stimu-
lus. Here, we did not aim to isolate the specific subcomponent
process that was affected by the drug, but rather we aimed to
test drug effects on an ecologically valid model of attention
switching. Nevertheless, it is notable that the regions within the
functional network that were affected by bromocriptine, in
particular the IFG and the basal ganglia, have previously been
associated with inhibition (Aron et al. 2007; Duann et al. 2009;
Zandbelt and Vink 2010). Similarly, the thalamus has been
implicated in the inhibition of ongoing behaviour and action
selection. More specifically, Ding et al. have proposed that
salient signals that are detected by the thalamus are transmitted
to the striatum via thalamo-striatal axonal connections, where
they elicit a characteristic firing pattern that is optimized for
halting ongoing (motor and cognitive) programmes (Ding et al.
2010). Their study revealed that activation of thalamo-striatal
axonsmimicked the response to salient stimuli in the sense that
it induced burst firing of striatal interneurons, which in turn
triggered prolonged enhancement of postsynaptic responsive-
ness of striatopallidal neurons. Critically, the effect of stimu-
lating the thalamus on striatal interneurons depended on D2
receptor stimulation. Accordingly, they proposed that effects of
D2 receptor agents on attention switching to salient events
might depend on axonal connections that enable thalamic
gating of striatopallidal signals (Ding et al. 2010). The findings
of the present study concur with this hypothesis. Thus, one
mechanism by which dopamine D2 receptor stimulation might
modulate attention switching to salient events is by affecting
thalamic signals to the striatum and subsequent flow through
fronto-striatal circuitry.
One important caveat of the present study is that we did not
find any drug effects on the behavioural measures of our task.
This was unexpected but might be accounted for by masking of
a subtle behavioural effect by noise induced by the scanner
environment. Perhaps, our measure of behaviour was not suf-
ficiently sensitive and thus masked by such non-specific
effects. Indeed, in a recent study in which subjects performed
the same attention switching paradigm outside the scanner, we
found that behavioural performance on the task was correlated
with FA values in the exact same basal ganglia region (van
Schouwenburg, Onnink, ter Huurne, Kan, Zwiers, Hoogman,
Franke, Buitelaar and Cools, Attention switching depends on
whitematter integrity of the basal ganglia: a study in adults with
ADHD, unpublished data). Nevertheless, the lack of a behav-
ioural effect in the current study does ensure that the observed
neural drug effects are not confounded by drug-related differ-
ences in performance. Thus, the present study establishes a
strong link between dopamine’s effects on the basal ganglia,
functional fronto-striatal connectivity during attention switching
and fronto-striato-thalamic anatomy. Future work should aim to
extend the link between fronto-striatal anatomy and dopaminer-
gic drug effects on fronto-striatal function to behaviour.
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